touchPODCAST
HPV infection and TGF-β: Translating the science into treatments for HPV-associated cancers

HPV infection and TGF-β: Translating the science into treatments for HPV-associated cancers

January 20, 2022

Listen to leading experts consider the current treatment options and unmet needs for patients with HPV-associated cancers, the link between HPV and TGF-β, and how this is driving the development of new treatments.

The experts

  • Dr Judith Michels, Institut Gustave Roussy, Villejuif, France
  • Dr Andrew Sikora, MD Anderson Cancer Center, Houston, TX, USA
  • Dr Krishnansu Tewari, University of California, Irvine, CA, USA

This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from GSK and Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. 

For further information visit our website:
https://touchoncologyime.org/hpv-associated-cancers/?_ga=2.151091262.621073815.1642410762-2024672127.1626340027

 

MDT and patient perspectives on the long-term management of patients with severe type 2 asthma - touchIMMUNOLOGY

MDT and patient perspectives on the long-term management of patients with severe type 2 asthma - touchIMMUNOLOGY

January 14, 2022

Listen to key experts from a multidisciplinary team, and a patient with severe asthma, discuss evidence-based guidance for the long-term management of patients with severe type 2 asthma. 

The multidisciplinary team 

  • Pulmonologist: Professor Alberto Papi, Italy
  • Allergist: Professor Ioana Agache, Romania
  • Primary care physician: Professor Barbara Yawn, USA
  • Patient: Ms JoJo O’Neal, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This medical education is jointly provided by USF Health and touchIME.

For further information visit: https://touchimmunologyime.org/

Immune checkpoint inhibitors in prostate cancer: Current and future practice

Immune checkpoint inhibitors in prostate cancer: Current and future practice

January 13, 2022

Listen to leading experts consider the current role of immune checkpoint inhibitors in prostate cancer and possible future directions.

The experts

  • Prof. Karim Fizazi - Gustave Roussy, Villejuif, France
  • Dr Sandy Srinivas - Stanford University, Stanford, CA, USA
  • Prof. Johann de Bono - The Institute of Cancer Research, London, UK

This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Merck Sharp & Dohme Corp. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/icis-prostate-cancer/

Targeting the underlying pathobiology of ESCC

Targeting the underlying pathobiology of ESCC

December 6, 2021

Listen to leading experts provide an update on the underlying pathobiology of esophageal squamous cell carcinoma, and review current and emerging therapies.

The expert

  • Prof. Ken Kato, National Cancer Center Hospital, Tokyo, Japan

This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an independent medical education grant from Novartis. This activity is provided by touchIME.

For further information visit our website: https://touchoncologyime.org/targeting-pathobio-of-ESCC-and-emerging-impact-of-IO

Experts discuss how endotyping and biomarkers can help to guide treatment selection in severe type 2 asthma - touchIMMUNOLOGY

Experts discuss how endotyping and biomarkers can help to guide treatment selection in severe type 2 asthma - touchIMMUNOLOGY

December 3, 2021

Listen to leading experts discuss the serious consequences of severe type 2 asthma, how endotyping and biomarkers can help guide treatment selection in such patients, and how recent data and clinical guidelines can inform the long-term management of patients with severe type 2 asthma.

 

The experts

  • Dr Katharine Woessner, Scripps Clinic Medical Group, San Diego, CA, USA
  • Prof. Louis-Philippe Boulet, Laval University, Quebec City, Canada 
  • Prof. Arnaud Bourdin, Arnaud de Villeneuve Hospital, Montpellier, France

 

This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an unrestricted independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.

 

For further information visit our website:  https://touchimmunologyime.org/endotypes-for-treatment-selection-in-severe-T2-asthma/

Experts discuss how endotyping and biomarkers can help to guide treatment selection in severe type 2 asthma - touchRESPIRATORY

Experts discuss how endotyping and biomarkers can help to guide treatment selection in severe type 2 asthma - touchRESPIRATORY

December 3, 2021

Listen to leading experts discuss the serious consequences of severe type 2 asthma, how endotyping and biomarkers can help guide treatment selection in such patients, and how recent data and clinical guidelines can inform the long-term management of patients with severe type 2 asthma.

 

The experts

  • Dr Katharine Woessner, Scripps Clinic Medical Group, San Diego, CA, USA
  • Prof. Louis-Philippe Boulet, Laval University, Quebec City, Canada 
  • Prof. Arnaud Bourdin, Arnaud de Villeneuve Hospital, Montpellier, France

 

This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an unrestricted independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.

 

For further information visit our website:  https://touchrespiratoryime.org/endotypes-for-treatment-selection-in-severe-T2-asthma/

Improving outcomes for patients with NTM-LD

Improving outcomes for patients with NTM-LD

November 30, 2021

touchEXPERT OPINIONS

Listen to leading experts consider how to optimize the diagnosis of nontuberculous mycobacterial lung disease (NTM-LD) and how to manage it considering the latest treatment guidelines.

The experts

  • Dr Juzar Ali, LSU Health Sciences Center, New Orleans, LA, USA
  • Dr Doreen Addrizzo-Harris, NYU Grossman School of Medicine, New York, NY, USA
  • Dr Kevin Winthrop, Oregon Health & Science University, Portland, OR, USA

This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Insmed. This activity is jointly provided by USF Health and touchIME. 

For further information visit our website: touchinfectiousdiseasesime.org/guideline-based-strategies-ntm-ld

 

Improving outcomes for patients with NTM-LD

Improving outcomes for patients with NTM-LD

November 30, 2021

touchEXPERT OPINIONS

Listen to leading experts consider how to optimize the diagnosis of nontuberculous mycobacterial lung disease (NTM-LD) and how to manage it considering the latest treatment guidelines.

The experts

  • Dr Juzar Ali, LSU Health Sciences Center, New Orleans, LA, USA
  • Dr Doreen Addrizzo-Harris, NYU Grossman School of Medicine, New York, NY, USA
  • Dr Kevin Winthrop, Oregon Health & Science University, Portland, OR, USA

 

This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Insmed. This activity is jointly provided by USF Health and touchIME. 

For further information visit our website: https://touchrespiratoryime.org/guideline-based-strategies-ntm-ld

Achieving sustained outcomes for moderate-to-severe atopic dermatitis

Achieving sustained outcomes for moderate-to-severe atopic dermatitis

November 30, 2021

This touchPODCAST is presented by Dr Melinda Gooderham, SKiN Centre for Dermatology, Peterborough, Ontario, Canada.

 

Listen to Dr Gooderham present the latest data and future directions of systemic therapy for moderate-to-severe atopic dermatitis and how effective treatment can achieve sustained control of symptoms and improve the quality of life of patients and their families.

 

This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an unrestricted independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. This activity is jointly provided by USF Health and touchIME.

 

For further information visit https://touchimmunologyime.org/systemic-therapy-atopic-dermatitis

Video 3 - MDT perspectives on the latest clinical data for targeted therapies for thyroid cancer

Video 3 - MDT perspectives on the latest clinical data for targeted therapies for thyroid cancer

November 30, 2021

Listen to key experts from a multidisciplinary team discuss the latest efficacy and safety data for targeted therapies for thyroid cancer 

 

The multidisciplinary team 

  • Endocrinologist: Dr Antonio Matrone, Italy
  • Nurse specialist: Ms Tara Hurley, UK
  • Oncologist: Dr Lori Wirth, USA

 

This touchPODCAST is for HCPs only.

 

This activity is funded by an independent medical education grant from Eli Lilly and Bayer. This medical education is jointly provided by USF Health and touchIME.

 

For further information visit: https://touchoncologyime.org/personalized-approach-to-treatment-thyroid-cancer-biomarkers-and-targeted-therapies//

Podbean App

Play this podcast on Podbean App